An Integrated Preclinical Platform for Lethal Neuroendocrine Prostate Cancer from Rapid Autopsy Bone and Liver Metastases.
Borum RyuiD, Thomas C. CaffreyiD, Sriya Sridhar, Catherine S. JohnsoniD, Ramia J. SalloomiD, Kabhilan MohaniD, Grace Waldron, Amanda RobothamiD, Ethan M Wilcox, Diane L. Costanzo-GarveyiD, Janice TayloriD, James Talaska, Rachel Rhatigan, Quan P. LyiD, Heather C. Jensen-Smith, Kaustubh DattaiD, Surinder K. Batra, Chad A. LaGrangeiD, Benjamin A. TeplyiD, Subodh M. LeleiD, Michael Anthony HollingsworthiD, R. Katherine HydeiD, Kyle J. HewittiD, Gargi GhosaliD, Fanben MengiD, , Grinu MathewiD
Abstract
Treatment-emergent neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant disease arising in up to 20% of castration resistant prostate cancers, yet robust biologically relevant preclinical models remain scarce. Here, we describe a technical blueprint for establishing an integrated platform of patient-derived models from visceral and bone metastases collected through a prostate cancer rapid autopsy program (PC RAP). We report the establishment and characterization of patient-derived xenograft (PDX) models from liver metastasis tissue, liver and bone metastasis-derived organoid lines (PDOs), and corresponding patient-derived organoid xenograft (PDOX) models. In addition, we established, to our knowledge, the first mesenchymal stem cell (MSC) cultures derived from neuroendocrine prostate cancer (NEPC) bone metastases. The PDOs preserved intratumoral heterogeneity, displaying both CRPC-NE and CRPC-adenocarcinoma features. These organoids retained neuroendocrine identity across multiple passages, with transcriptomic profiles concordant with the original patient tissue and matched PDX models generated at our institution and at the National Cancer Institute (NCI Patient-Derived Models Repository). To model the bone metastatic microenvironment, we generated novel organoid-based New Approach Methodologies (NAMs) by co-culturing PDOs with iPSC-derived bone marrow organoids, establishing a physiologically relevant vascularized organotypic model of PC bone metastasis. To extend our studies in vivo, we established preclinical models using the liver and bone metastasis-derived organoid models. The PDOX models were tumorigenic and developed spontaneous lymph node metastases, providing clinically relevant models for investigating lethal NEPC biology. Together, these complementary patient-derived models provide a robust and versatile platform for investigating NEPC biology, metastatic progression, and evaluating new therapeutic strategies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=184 SRC="FIGDIR/small/740121v1_ufig1.gif" ALT="Figure 1"> View larger version (57K): org.highwire.dtl.DTLVardef@1c641f1org.highwire.dtl.DTLVardef@113696aorg.highwire.dtl.DTLVardef@16dcc72org.highwire.dtl.DTLVardef@1898d9f_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LINovel preclinical models of visceral and bone metastases established from a prostate cancer rapid autopsy program. C_LIO_LIThis study is the first to establish mesenchymal stem cell cultures from NEPC bone metastases. C_LIO_LIPDOs preserve heterogeneity, showing both CRPC-NE and CRPC-Adeno features, with transcriptomic profiles concordant with originator tissue and PDX models. C_LIO_LIPC RAP-derived organoids are tumorigenic in vivo and generate spontaneous lymph node metastases. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dual-lineage human 3D bone niche model reveals osteoclast-driven osteomimicry in prostate cancer
Andrea Mazzoleni, Robin Dolgos, … Iván Martín·bioRxiv·Nov 18, 2025
- ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types
Robin Dolgos, Romuald Parmentier, … Clémentine Le Magnen·Cell ReportsPeer-reviewed·Oct 1, 2025
- Patient-derived xenografts and organoids model therapy response in prostate cancer
S. Karkampouna, F. La Manna, … M. Kruithof-de Julio·Nature CommunicationsPeer-reviewed·Feb 18, 2021
- NEUROG3 Is Sufficient to Drive Neuroendocrine Differentiation in Prostate Cancer Cells.
Abdelkader Daoud, Lu Han, … Jorge O. Múnera·bioRxiv·Nov 10, 2025
- A modular patient-derived organoid-xenograft platform reveals molecular and clinical trajectories of prostate cancer progression
Romuald Parmentier, Robin Dolgos, … Clémentine Le Magnen·bioRxiv·Jan 5, 2026
- The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
Rodrigo Romero, Tinyi Chu, … Charles L. Sawyers·Nature CancerPeer-reviewed·Oct 11, 2024